Casdin Capital’s Acceleron Pharma XLRN Stock Holding History

Casdin Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-45,000	Closed	-$1.15M	–	33
2016 Q4	$1.15M	Buy	+45,000	New	+$1.43M	0.95%	23

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Casdin Capital's XLRN Position: Q1 2017 in Review

Casdin Capital sold out of Acceleron Pharma (XLRN) in Q1 2017, closing a stake of 45,000 shares — an estimated $1.15M sold.

Casdin Capital first reported a position in XLRN in Q4 2016 and held it in 1 quarter. The position peaked at $1.15M in Q4 2016. 136 funds tracked by Wall St. Rank hold XLRN as of Q1 2017.

Casdin Capital reported no remaining Acceleron Pharma position as of Q1 2017 after selling out during the quarter.
Casdin Capital sold 45,000 Acceleron Pharma shares in Q1 2017, an estimated $1.15M.
Casdin Capital first reported a position in Acceleron Pharma in Q4 2016 and held it in 1 quarter.
Casdin Capital's Acceleron Pharma position peaked at $1.15M in Q4 2016.
136 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2017.

Based on Casdin Capital's 13F filing for Q1 2017, filed 15 May 2017.